Kerendia — Medical Mutual

Diabetic Kidney Disease

Initial criteria

Patient is ≥ 18 years of age; AND
Patient has a diagnosis of type 2 diabetes; AND
Patient meets one of the following (a or b): a) Patient is currently receiving a maximally tolerated labeled dosage of angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB); OR b) According to the prescriber, patient has a contraindication to ACE inhibitor or ARB therapy; AND
At baseline (prior to the initiation of Kerendia), patient meets all of the following (a, b, and c): a) Estimated glomerular filtration rate ≥ 25 mL/min/1.73 m2 OR stage 2, 3, or 4 CKD; AND b) Urine albumin-to-creatinine ratio ≥ 30 mg/g; AND c) Serum potassium level ≤ 5.0 mEq/L.

Patient is ≥ 18 years of age; AND
Patient has a diagnosis of type 2 diabetes; AND
Patient meets one of the following (a or b): a) Patient is currently receiving a maximally tolerated labeled dosage of angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB); OR b) According to the prescriber, patient has a contraindication to ACE inhibitor and ARB therapy.

365 days